Residency · Residency · Endocrinology

Hyperthyroidism - Graves Disease and Toxic Nodular Goiter

Overview of Thyrotoxicosis vs Hyperthyroidism

Definitions

A critical conceptual distinction must be drawn at the outset between thyrotoxicosis and hyperthyroidism, as these terms are often used interchangeably but are not synonymous. Thyrotoxicosis refers to the clinical syndrome resulting from excess thyroid hormone exposure from any source, whether endogenous or exogenous. Hyperthyroidism is a subset of thyrotoxicosis in which the excess thyroid hormone arises specifically from increased synthesis and secretion by the thyroid gland itself. This distinction carries direct therapeutic implications: destructive thyroiditis causes thyrotoxicosis but not hyperthyroidism, and accordingly, radioactive iodine uptake is suppressed and antithyroid drugs are ineffective because the problem is not overproduction but rather uncontrolled release of preformed hormone from damaged follicles.

Epidemiology

The overall prevalence of hyperthyroidism is approximately 1.2 to 1.6%, comprising 0.5% overt disease and 0.7% subclinical hyperthyroidism. Graves disease accounts for 60 to 80% of hyperthyroidism in iodine-sufficient regions, with peak incidence between ages 30 and 50 and a striking female-to-male ratio of 5 to 10:1. Toxic multinodular goiter (TMNG) predominates in elderly populations and in iodine-deficient regions, while toxic adenoma accounts for approximately 3 to 5% of hyperthyroidism cases.

Graves Disease

Pathophysiology

Graves disease is an autoimmune disorder driven by thyroid-stimulating immunoglobulins (TSI), which are IgG1 antibodies that bind to and activate the TSH receptor. These antibodies mimic TSH action by engaging the Gs-cAMP-PKA signaling pathway within thyroid follicular cells, resulting in diffuse thyroid hyperplasia, increased iodine uptake, and excess T4 and T3 synthesis and secretion. Because thyroid stimulation is driven by autoantibodies rather than TSH, the gland becomes autonomous from the normal hypothalamic-pituitary-thyroid axis. TSH is profoundly suppressed by the resulting thyroid hormone excess, yet thyroid stimulation continues unabated.

Genetic susceptibility involves multiple loci, including HLA-DR3 in Caucasian populations, CTLA-4, PTPN22, thyroglobulin gene variants, CD40, and FOXP3. Environmental triggers include psychological stress (particularly major life events), smoking (the strongest modifiable risk factor, with a particularly pronounced effect on the development and severity of Graves ophthalmopathy), the postpartum period, excess iodine exposure, and possibly infection, with molecular mimicry between Yersinia enterocolitica and the TSH receptor being a longstanding but debated hypothesis. The marked female predominance is thought to relate to X-chromosome inactivation skewing and estrogen-mediated effects on immune regulation.

Clinical Features

The clinical manifestations of Graves disease reflect the systemic effects of thyroid hormone excess on virtually every organ system. Metabolic features include weight loss despite increased appetite, heat intolerance, and diaphoresis, driven by an elevated basal metabolic rate. Cardiovascular manifestations are prominent and include resting tachycardia above 90 beats per minute, palpitations, widened pulse pressure, systolic hypertension, high-output heart failure, and atrial fibrillation, which occurs in 10 to 15% of patients with increasing frequency with age.

Neuromuscular findings include a fine, high-frequency tremor, proximal muscle weakness (thyrotoxic myopathy), hyperreflexia, and, particularly in Asian males, hypokalemic periodic paralysis. Gastrointestinal manifestations include intestinal hypermotility with increased stool frequency and, rarely, malabsorption. Neuropsychiatric symptoms range from anxiety, irritability, insomnia, and emotional lability to, in extreme cases, frank psychosis. Dermatologic findings include warm moist skin, palmar erythema, onycholysis, and diffuse alopecia. Reproductive effects include oligomenorrhea and infertility in women, and gynecomastia in men due to increased SHBG and aromatase activity. Skeletal effects include accelerated bone turnover, osteoporosis predominantly affecting cortical bone, and hypercalcemia with hypercalciuria.

Graves-Specific Manifestations

Several manifestations are unique to Graves disease and do not occur in other causes of thyrotoxicosis. Graves ophthalmopathy (GO), also termed thyroid eye disease (TED), occurs clinically in 25 to 50% of patients, though subclinical orbital changes can be detected on CT or MRI in up to 70%. The pathogenesis involves autoimmune-mediated inflammation targeting TSH receptors and IGF-1 receptors expressed on orbital fibroblasts, leading to glycosaminoglycan deposition and adipogenesis within the orbital fat and extraocular muscles. Clinical features include periorbital edema, proptosis (exophthalmos), lid retraction (the most common sign, known as Dalrymple sign), lid lag (von Graefe sign), conjunctival injection, chemosis, diplopia (with the inferior rectus being the most commonly affected muscle), and exposure keratopathy.

Disease activity is assessed using the Clinical Activity Score (CAS), a 7-point scale in which a score of 3 or greater indicates active inflammatory disease amenable to immunosuppressive therapy. The EUGOGO severity classification categorizes GO as mild (minimal impact on daily life), moderate-to-severe (significant impact with diplopia or proptosis of 3 mm or more), or sight-threatening. Dysthyroid optic neuropathy (DON) represents the most serious complication, resulting from compressive optic neuropathy caused by enlarged extraocular muscles at the orbital apex, and constitutes an emergency requiring intravenous glucocorticoids with or without surgical decompression.

Graves dermopathy (pretibial myxedema), occurring in 1 to 4% of patients, results from localized dermal accumulation of glycosaminoglycans, producing waxy, non-pitting, peau d'orange skin changes typically on the anterolateral shins. It is almost always associated with severe ophthalmopathy. Thyroid acropachy, the rarest manifestation at less than 1%, consists of digital clubbing and periosteal new bone formation, and is similarly associated with severe ophthalmopathy and dermopathy.

<image>A clinical composite illustration of Graves disease manifestations. Central figure shows a female patient with: diffuse goiter with audible bruit, staring gaze with lid retraction and periorbital edema, fine tremor of outstretched hands, tachycardia (heart rate display showing 110 bpm). Surrounding panels show: (1) Close-up of eyes with proptosis, lid retraction, conjunctival injection and chemosis, (2) Pretibial myxedema on anterior shins showing raised waxy plaques with peau d'orange texture, (3) Thyroid acropachy showing digital clubbing and periosteal bone changes on hand X-ray, (4) Thyroid scintigraphy showing diffuse homogeneous uptake. Use realistic medical illustration style with labeled annotations.</image>

Diagnosis of Graves Disease

The biochemical hallmark is a suppressed TSH, typically below 0.01 mIU/L, with elevated free T4 and free T3. T3 is often disproportionately elevated, with a T3-to-T4 ratio exceeding 20:1, reflecting enhanced thyroidal T3 production under TSI stimulation. TSH receptor antibodies (TRAb or TSI) are positive in more than 95% of Graves patients and are diagnostic, particularly useful when radioactive iodine uptake is unavailable (as in pregnancy) or when differentiation from thyroiditis is needed. RAIU demonstrates elevated uptake (above 30%) with diffuse homogeneous uptake on scan but is not required when TRAb is positive and the clinical presentation is classic. Anti-TPO antibodies are positive in 70 to 80% of Graves patients, reflecting coexistent Hashimoto autoimmunity. Thyroid ultrasound shows diffuse enlargement, heterogeneous echotexture, and markedly increased vascularity, producing the characteristic "thyroid inferno" pattern on color Doppler imaging.

Management of Graves Disease

Antithyroid Drugs (ATDs)

Methimazole (MMI) is the preferred antithyroid drug in most clinical situations, started at 10 to 30 mg daily depending on disease severity and titrated to a maintenance dose of 5 to 10 mg daily. Propylthiouracil (PTU), dosed at 100 to 200 mg three times daily, is preferred in two specific settings: the first trimester of pregnancy (due to methimazole's teratogenic effects including aplasia cutis, choanal atresia, and esophageal atresia) and thyroid storm (where PTU's additional inhibition of peripheral T4-to-T3 conversion via D1 provides therapeutic advantage). Carbimazole, a prodrug of methimazole used in the United Kingdom and Europe, is dosed at 15 to 40 mg daily.

Both drugs inhibit TPO-catalyzed organification and coupling reactions, with PTU also inhibiting peripheral D1-mediated T4-to-T3 conversion. A block-and-replace regimen combining high-dose ATD with levothyroxine may reduce relapse in some studies but is not recommended during pregnancy. Treatment is typically continued for 12 to 18 months, after which TRAb levels are checked before discontinuation. A negative TRAb at discontinuation predicts approximately 50% long-term remission, while persistent TRAb positivity predicts more than 80% relapse. Overall remission rates after a course of ATDs are approximately 40 to 50%, with higher rates in female patients with small goiters, mild hyperthyroidism, negative TRAb at discontinuation, and non-smokers.

Side effects range from minor (rash, urticaria, arthralgias, and GI upset in 5 to 25%, which may be managed by switching to the other ATD) to serious but rare. Agranulocytosis, defined as an absolute neutrophil count below 500/mm3, occurs in 0.2 to 0.5% and is idiosyncratic and rapid in onset. Patients must be instructed to check a white blood cell count urgently if they develop fever or sore throat, and the ATD must be discontinued immediately, with G-CSF administered in severe cases. Rechallenge with either the same or alternative ATD is contraindicated. PTU carries an FDA black box warning for potentially fatal hepatocellular toxicity, whereas methimazole-associated hepatotoxicity is typically cholestatic and usually reversible. ANCA-positive vasculitis is more common with PTU and can cause glomerulonephritis and pulmonary hemorrhage.

Radioactive Iodine (RAI) Therapy

RAI therapy using I-131 at doses of 10 to 15 mCi (370 to 555 MBq), adjusted for thyroid size and RAIU, provides definitive treatment through beta radiation-mediated destruction of thyroid follicular cells. The effect evolves over 6 to 18 weeks. Hypothyroidism is the expected and desirable outcome, occurring in 50 to 80% by one year, with lifelong levothyroxine replacement required. ATDs are typically stopped 3 to 7 days before RAI (or 2 weeks for PTU, which has a radioprotective effect), with beta-blockers used for symptom control in the interim.

A specific concern with RAI in Graves disease is the 15 to 20% risk of new or worsened Graves ophthalmopathy, with risk factors including smoking, severe or active pre-existing GO, and high TRAb levels. This risk is effectively mitigated by concurrent oral prednisone at 0.3 to 0.5 mg/kg/day, initiated on the day of RAI and tapered over 3 months. Contraindications to RAI include pregnancy, breastfeeding, inability to comply with radiation safety precautions, coexistent thyroid cancer, very large goiter (relative), and severe active ophthalmopathy (relative).

Thyroidectomy

Total or near-total thyroidectomy by an experienced surgeon (performing more than 25 thyroidectomies per year) provides definitive treatment. Indications include large goiter exceeding 80 grams, suspicious or confirmed thyroid nodules, moderate-to-severe active ophthalmopathy (where RAI would be contraindicated), contraindications to both ATDs and RAI, patient preference, and women planning near-term pregnancy. Patients should be rendered euthyroid with ATDs before surgery. In urgent situations, Lugol solution (potassium iodide drops, 5 to 10 drops three times daily for 7 to 10 days preoperatively) reduces thyroid vascularity and hormone release through the Wolff-Chaikoff effect. Complications include transient hypoparathyroidism (10 to 20%), permanent hypoparathyroidism (1 to 3%), recurrent laryngeal nerve injury (transient 3 to 5%, permanent less than 1%), bleeding or hematoma (less than 1%), and hypothyroidism (expected, requiring immediate postoperative levothyroxine initiation).

<image>A treatment decision algorithm for Graves disease. Start with confirmed Graves disease (suppressed TSH, elevated T4/T3, positive TRAb or diffuse uptake on scan). Three main branches: (1) Antithyroid drugs - show indications (first episode, small goiter, mild disease, pregnancy), duration 12-18 months, check TRAb before stopping; (2) Radioactive iodine - show indications (relapse after ATDs, moderate goiter, patient preference), contraindications (pregnancy, severe active GO), GO precaution box (concurrent prednisone); (3) Surgery - show indications (large goiter, coexistent nodule, severe GO, ATD failure). Include a box for adjunctive therapy applicable to all: beta-blockers (propranolol 20-40 mg TID or atenolol 25-100 mg daily). Show outcomes for each pathway. Use clean flowchart with color-coded branches.</image>

Toxic Multinodular Goiter (TMNG)

Pathophysiology

Toxic multinodular goiter results from the autonomous function of one or more thyroid nodules that operate independently of TSH stimulation. The molecular basis in most cases is somatic activating mutations in the TSH receptor gene (60 to 70% of autonomous nodules) or Gs-alpha mutations (gsp mutations, in 5 to 10%). The natural history is one of gradual progression from a euthyroid multinodular goiter through subclinical hyperthyroidism to overt hyperthyroidism, a process evolving over years to decades. TMNG is more prevalent in iodine-deficient regions and elderly populations, and iodine supplementation or iodine-containing contrast agents can precipitate overt hyperthyroidism through the Jod-Basedow phenomenon.

Clinical Features

Patients with TMNG are typically older, beyond 50 to 60 years of age, with a longstanding history of goiter. Symptoms are often milder or atypical compared to Graves disease. Atrial fibrillation, unexplained weight loss, and apathy (the so-called "apathetic thyrotoxicosis" of the elderly) may be the presenting features rather than the classic hyperadrenergic symptoms. Large goiters may produce compressive symptoms including dysphagia, dyspnea, stridor, and hoarseness, with substernal or retrosternal extension present in 15 to 30% of large multinodular goiters. Importantly, ophthalmopathy, dermopathy, and acropachy do not occur in TMNG, as these manifestations are specific to the autoimmune process of Graves disease.

Diagnosis

Biochemically, TSH is suppressed with elevation of free T4 and/or free T3, with T3 thyrotoxicosis being common. TRAb is negative, which distinguishes TMNG from Graves disease. RAIU shows normal to elevated overall uptake, with the scan demonstrating heterogeneous or patchy uptake with hot and cold areas reflecting the mixture of autonomous and non-autonomous tissue. Ultrasound reveals multiple nodules of varying echogenicity, and any suspicious nodules should be evaluated with FNA. CT without contrast (if RAI is planned) assesses substernal extension and tracheal deviation or compression.

Management

ATDs can control hyperthyroidism in TMNG but do not provide cure; relapse is universal upon discontinuation, making ATDs primarily a temporizing measure for preoperative preparation or for patients unfit for definitive therapy. RAI is effective but often requires higher doses than in Graves disease (15 to 30 mCi) due to lower uptake per nodule, achieving euthyroidism in 50 to 60% with potential need for repeated dosing. Goiter reduction of 40 to 50% can be expected over 2 years. Pretreatment with low-dose recombinant TSH (0.1 mg) to enhance iodine uptake is used in some European centers but is not FDA-approved for this indication. Surgery, specifically total thyroidectomy, is preferred for large goiters exceeding 80 grams, compressive symptoms, substernal extension, or suspected malignancy within nodules. Percutaneous ethanol injection and radiofrequency ablation have limited roles in TMNG but may be applicable for single toxic adenomas.

Toxic Adenoma (Plummer Disease)

Pathophysiology

A toxic adenoma is a single autonomously functioning thyroid nodule with constitutive activation of TSH receptor signaling. Somatic TSH receptor mutations are found in more than 70% of cases, with somatic Gs-alpha mutations accounting for an additional 5 to 10%. Nodules typically need to reach 2.5 to 3 cm in diameter before producing enough hormone to cause overt hyperthyroidism, though smaller nodules may cause subclinical disease.

Diagnosis

The diagnostic hallmark is a thyroid scintigraphy scan showing a single hot nodule with suppressed uptake in the surrounding thyroid tissue. The malignancy risk in hot nodules is very low, at less than 1 to 3%, substantially lower than in cold nodules. FNA is generally not indicated for hot nodules unless the ultrasound features are independently concerning.

Management

RAI at doses of 15 to 29 mCi provides effective targeted ablation of the autonomous nodule, with the advantage that surrounding suppressed tissue, being relatively protected from radiation, is spared. The resulting hypothyroidism rate is lower than with Graves disease RAI treatment, at approximately 10 to 20%. Surgical lobectomy is curative and avoids the need for lifelong levothyroxine in most patients. Radiofrequency ablation (RFA) and percutaneous ethanol injection are emerging alternatives for benign toxic nodules, used particularly in Europe and Asia, that may avoid surgery and RAI while achieving volume reductions of 50 to 80%.

Subclinical Hyperthyroidism

Definition and Risk Stratification

Subclinical hyperthyroidism is defined as a suppressed TSH with normal free T4 and free T3, confirmed on repeat testing 3 to 6 months apart. It is stratified into two grades: grade 1 (mild), with TSH between 0.1 and 0.39 mIU/L and lower risk, and grade 2 (severe), with TSH below 0.1 mIU/L and higher risk.

Adverse Outcomes

Even in the absence of overt thyroid hormone elevation, subclinical hyperthyroidism carries clinically significant risks. The risk of atrial fibrillation is increased, with relative risks of 1.7 for grade 1 and 2.5 for grade 2 in patients over 65 years. Osteoporosis and fractures are accelerated, primarily in postmenopausal women through increased cortical bone loss. Cardiovascular mortality is increased in grade 2 disease, especially in those over 65. Associations with cognitive decline and dementia have also been reported in elderly populations.

Treatment Recommendations

For grade 2 subclinical hyperthyroidism (TSH below 0.1 mIU/L), treatment is recommended in patients over 65, those with cardiac disease, osteoporosis, or postmenopausal status, and should be strongly considered in all patients. For grade 1 disease (TSH 0.1 to 0.39 mIU/L), treatment is indicated for patients over 65 with cardiac risk factors or osteoporosis, while younger asymptomatic patients may be observed with repeat testing. The treatment approach mirrors that for overt hyperthyroidism based on the underlying cause.

Adjunctive Therapy for All Causes

Beta-Blockers

Beta-blockers provide symptomatic relief of adrenergic manifestations across all causes of thyrotoxicosis. Propranolol, dosed at 20 to 40 mg three to four times daily, is the preferred agent because it also inhibits peripheral T4-to-T3 conversion through D1 inhibition. Atenolol, a cardioselective agent at 25 to 100 mg daily, does not share this deiodination-inhibiting property. The target heart rate is 60 to 80 beats per minute, and therapy is continued until the euthyroid state is achieved. In patients with severe asthma, cardioselective agents should be used with caution, and diltiazem or verapamil may serve as alternatives.

Other Supportive Measures

Calcium and vitamin D supplementation addresses the increased bone resorption associated with thyrotoxicosis. Anticoagulation for atrial fibrillation follows standard guidelines. Cholestyramine at 4 grams four times daily binds thyroid hormones in the enterohepatic circulation and serves as a useful adjunct in severe thyrotoxicosis. Glucocorticoids inhibit peripheral T4-to-T3 conversion and are particularly important in thyroid storm management.

Graves Ophthalmopathy Management

Mild Disease

Management of mild Graves ophthalmopathy relies on local measures including artificial tears, sunglasses, sleeping with the head elevated, and selenium supplementation at 200 mcg daily, which demonstrated modest benefit in a EUGOGO randomized controlled trial. Smoking cessation is the single most important modifiable factor, as smokers have more severe and treatment-resistant ophthalmopathy.

Moderate-to-Severe Active Disease

For moderate-to-severe active GO, intravenous methylprednisolone pulses represent the first-line treatment, administered as 500 mg weekly for 6 weeks followed by 250 mg weekly for 6 weeks (total cumulative dose of 4.5 grams). This regimen is superior to oral prednisone with fewer systemic side effects, though the cumulative dose should not exceed 8 grams due to hepatotoxicity risk.

Teprotumumab, an anti-IGF-1 receptor monoclonal antibody approved by the FDA in 2020, has been a transformative advance. Administered as 8 infusions over 24 weeks, it produces significant improvement in proptosis (mean reduction of 2.8 mm), diplopia, and CAS. It is the only therapy demonstrated to significantly reduce proptosis in GO. The cost is approximately $300,000 per course, and adverse effects include hearing loss (10%) and hyperglycemia. Mycophenolate mofetil at 360 to 720 mg twice daily provides steroid-sparing efficacy, with the MINGO trial demonstrating non-inferiority to intravenous steroids for moderate GO. Orbital radiotherapy delivering 20 Gy in 10 fractions serves as an adjunct to steroids but should be avoided in patients with diabetic retinopathy.

Sight-Threatening Disease (Dysthyroid Optic Neuropathy)

Dysthyroid optic neuropathy constitutes an emergency requiring intravenous methylprednisolone at 1 gram daily for 3 days followed by a taper. If no clinical response is evident within 1 to 2 weeks, urgent orbital decompression surgery must be performed.

Key Clinical Pearls

• T3 thyrotoxicosis (elevated T3 with normal T4) occurs in 5% of hyperthyroidism; more common in Graves and toxic nodular disease; always check free T3 when TSH is suppressed and free T4 is normal
• Apathetic thyrotoxicosis in the elderly may present with weight loss, atrial fibrillation, and depression without classic hyperadrenergic symptoms; check TSH in any elderly patient with unexplained AF or weight loss
• PTU is preferred over methimazole ONLY in first trimester of pregnancy and thyroid storm; in all other situations, methimazole is safer and more effective
• Iodinated contrast dye contains massive amounts of iodine (up to 13,000 mg per dose); can trigger Jod-Basedow phenomenon in patients with autonomous thyroid nodules; conversely, can worsen Graves by providing substrate
• Teprotumumab has fundamentally changed the management of moderate-to-severe active Graves ophthalmopathy; it is the only therapy shown to significantly reduce proptosis
• After RAI for Graves disease, concurrent oral prednisone (0.3-0.5 mg/kg, tapered over 3 months) should be given to patients at risk for GO worsening (smokers, active GO, high TRAb)

References

1. Ross DS, et al. "2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis." Thyroid. 2016;26(10):1343-1421.
2. Smith TJ, Hegedus L. "Graves' Disease." N Engl J Med. 2016;375(16):1552-1565.
3. Douglas RS, et al. "Teprotumumab for the Treatment of Active Thyroid Eye Disease." N Engl J Med. 2020;382(4):341-352.
4. Bartalena L, et al. "The 2021 European Group on Graves' Orbitopathy (EUGOGO) Clinical Practice Guidelines for the Medical Management of Graves' Orbitopathy." Eur J Endocrinol. 2021;185(4):G43-G67.
5. Burch HB, Cooper DS. "Management of Graves Disease: A Review." JAMA. 2015;314(23):2544-2554.

Read this lecture as Markdown